The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Open accessAbstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [34]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Cited by
Sorted by citations
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
Self-citationBrudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792
Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Self-citationEpidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
“Lastly, immunomodulators like lenalidomide, pomalidomide, and thalidomide are frequently used in triplet or quadruplet induction regimens and maintenance regimens [33,34].”
Background
Metadata
- Authors
- Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., Jurczyszyn, A., Ludwig, H., Mellqvist, U.-H., Chng, W.-J., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, C. S., Mazumder, A., Westin, J., Lu, J., Reiman, T., Kristinsson, S., Joshua, D., Roussel, M., O'Gorman, P., Terpos, E., McCarthy, P., Dimopoulos, M., Moreau, P., Orlowski, R. Z., Miguel, J. S., Anderson, K. C., Palumbo, A., Kumar, S., Rajkumar, V, Durie, B., & Richardson, P. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Antoine (FR)
- University of California, San Francisco (US)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire de Liège (BE)
- Istanbul Memorial Hospital (TR)
- University of North Carolina at Chapel Hill (US)
- Centre Hospitalier Universitaire de Lille (FR)
- Aalborg University Hospital (DK)
- King's College Hospital (GB)
- Jagiellonian University (PL)
- Wilhelminen Hospital (AT)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- University of Alberta (CA)
- Universitätsklinikum Würzburg (DE)
- Second Military Medical University (CN)
- Skåne University Hospital (SE)
- University of Bologna (IT)
- Queen Mary Hospital (CN)
- NYU Langone Health (US)
- Peking University People's Hospital (CN)
- Dalhousie University (CA)
- Royal Prince Alfred Hospital (AU)
- Hôpital Purpan (FR)
- National and Kapodistrian University of Athens (GR)
- Roswell Park Comprehensive Cancer Center (US)
- Nantes Université (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Turin (IT)
- Mayo Clinic (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Richardson, P G
- ORCID
- Laubach, J
- Garderet, L
- Caers, J
- Sezer, O
- Voorhees, P
- Leleu, X
- Johnsen, H E
- Streetly, M
- Jurczyszyn, A
- Ludwig, H
- Einsele, H
- Hou, J
- Turesson, I
- Zamagni, E
- Chim, C S
- Mazumder, A
- Reiman, T
- Kristinsson, S
- Roussel, M
- Terpos, E
- McCarthy, P
- Dimopoulos, M
- Moreau, P
- Orlowski, R Z
- Anderson, K C
- Palumbo, A
- Kumar, S
- Durie, B
- Richardson, P G
- Venue
- Leukemia
- Published
- 2015-12-29
- Volume
- 30
- Issue
- 5
- Pages
- 1005-1017
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2216303864
- Cited by
- 258
- References
- 133
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 33 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 10
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- relapsed multiple myeloma, relapsed/refractory multiple myeloma, second relapse, autologous stem cell transplantation, allogeneic stem cell transplantation, conventional-dose chemotherapy, diagnostic assessment, treatment selection
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Recurrence, Salvage Therapy, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
